Following the completion of Phase I (Sept. 2022–Aug. 2024), carried out by the University Medical Center Göttingen, Phase II was implemented by myotwin GmbH and ran until the end of March 2025.
“We are very grateful for the support provided through the EXIST Research Transfer. It paved the way for us to bring our technology from research into practical application,” says Andreas Meyer-Borgstädt, co-founder and CEO of myotwin. “Our special thanks go to the Project Management Jülich, the University Medical Center Göttingen, and the University of Göttingen for their valuable support.”
With the successful completion of the EXIST Research Transfer, myotwin is well positioned to further pursue its mission: developing a digital twin of the human heart. This platform aims to make drug development for cardiovascular diseases faster, safer, and free of animal testing – ultimately benefiting millions of patients worldwide.
About myotwin
myotwin is a biotech company specializing in human–relevant, preclinical testing systems for the development of cardiovascular drugs. With its proprietary myoScreen platform, myotwin enables the simultaneous measurement of contraction force, tissue stiffness, calcium dynamics, and electrical activity—directly on human heart tissue.
As a next step, myotwin is developing myoAI, a digital twin of the heart muscle that uses artificial intelligence to predict the efficacy and toxicity of drugs. This is giving rise to a new generation of precise, data-driven drug development.
The Germany-based company works closely with research institutions, industry partners, and investors to advance innovative therapies for cardiovascular diseases more quickly and in a more targeted manner. For more information, visit www.myotwin.com.
Forward–looking statements
This communication may contain forward–looking statements based on current assumptions and forecasts made by myotwin’s management. Various known and unknown risks, uncertainties, and other factors could cause the actual results, financial position, development, or performance of the company to differ materially from the estimates given here. These factors include those described in myotwin’s public reports, which are available on the myotwin website at www.myotwin.com. The company assumes no obligation to update such forward-looking statements or to adapt them to future events or developments.
